Epigenetic modulators as therapeutic targets in prostate cancer

Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/...

Descripción completa

Detalles Bibliográficos
Autores principales: Graça, Inês, Pereira-Silva, Eva, Henrique, Rui, Packham, Graham, Crabb, Simon J., Jerónimo, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025578/
https://www.ncbi.nlm.nih.gov/pubmed/27651838
http://dx.doi.org/10.1186/s13148-016-0264-8
_version_ 1782453980478046208
author Graça, Inês
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
author_facet Graça, Inês
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
author_sort Graça, Inês
collection PubMed
description Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
format Online
Article
Text
id pubmed-5025578
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50255782016-09-20 Epigenetic modulators as therapeutic targets in prostate cancer Graça, Inês Pereira-Silva, Eva Henrique, Rui Packham, Graham Crabb, Simon J. Jerónimo, Carmen Clin Epigenetics Review Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management. BioMed Central 2016-09-15 /pmc/articles/PMC5025578/ /pubmed/27651838 http://dx.doi.org/10.1186/s13148-016-0264-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Graça, Inês
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
Epigenetic modulators as therapeutic targets in prostate cancer
title Epigenetic modulators as therapeutic targets in prostate cancer
title_full Epigenetic modulators as therapeutic targets in prostate cancer
title_fullStr Epigenetic modulators as therapeutic targets in prostate cancer
title_full_unstemmed Epigenetic modulators as therapeutic targets in prostate cancer
title_short Epigenetic modulators as therapeutic targets in prostate cancer
title_sort epigenetic modulators as therapeutic targets in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025578/
https://www.ncbi.nlm.nih.gov/pubmed/27651838
http://dx.doi.org/10.1186/s13148-016-0264-8
work_keys_str_mv AT gracaines epigeneticmodulatorsastherapeutictargetsinprostatecancer
AT pereirasilvaeva epigeneticmodulatorsastherapeutictargetsinprostatecancer
AT henriquerui epigeneticmodulatorsastherapeutictargetsinprostatecancer
AT packhamgraham epigeneticmodulatorsastherapeutictargetsinprostatecancer
AT crabbsimonj epigeneticmodulatorsastherapeutictargetsinprostatecancer
AT jeronimocarmen epigeneticmodulatorsastherapeutictargetsinprostatecancer

Ejemplares similares